209,708 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Purchased by Wellington Management Group LLP

Wellington Management Group LLP acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 209,708 shares of the company's stock, valued at approximately $793,000. Wellington Management Group LLP owned about 0.24% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Mackenzie Financial Corp lifted its position in shares of Amylyx Pharmaceuticals by 234.9% during the 4th quarter. Mackenzie Financial Corp now owns 111,310 shares of the company's stock valued at $421,000 after acquiring an additional 78,070 shares during the last quarter. Alpine Global Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $45,000. Two Sigma Investments LP lifted its position in shares of Amylyx Pharmaceuticals by 77.4% during the 4th quarter. Two Sigma Investments LP now owns 651,517 shares of the company's stock valued at $2,463,000 after acquiring an additional 284,280 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $249,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $1,315,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. TD Cowen assumed coverage on Amylyx Pharmaceuticals in a research report on Friday, May 30th. They issued a "buy" rating for the company. Mizuho raised their target price on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 14th. HC Wainwright raised their target price on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Leerink Partnrs raised Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Finally, Leerink Partners raised Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $4.00 to $10.00 in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $9.83.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 21,490 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $74,570.30. Following the transaction, the chief executive officer now directly owns 3,355,280 shares in the company, valued at $11,642,821.60. This trade represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernhardt G. Zeiher bought 10,000 shares of the business's stock in a transaction on Thursday, March 20th. The shares were bought at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company's stock, valued at approximately $37,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 44,811 shares of company stock worth $155,494 over the last three months. Corporate insiders own 11.70% of the company's stock.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX traded down $0.34 during midday trading on Wednesday, hitting $5.42. 859,850 shares of the stock were exchanged, compared to its average volume of 1,201,540. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $7.27. The business's fifty day simple moving average is $4.70 and its two-hundred day simple moving average is $4.15. The company has a market capitalization of $483.14 million, a PE ratio of -1.42 and a beta of -0.59.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.03. As a group, equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.